Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-01-03 DOI:10.1016/j.clml.2024.12.021

Wan-Hsuan Lee , Chien-Chin Lin , Xavier Cheng-Hong Tsai , Feng-Ming Tien , Min-Yen Lo , Yuan-Yeh Kuo , Shan-Chi Yu , Ming-Chih Liu , Chang-Tsu Yuan , Ming Yao , Bor-Sheng Ko , Hwei-Fang Tien , Hsin-An Hou , Wen-Chien Chou

{"title":"Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends","authors":"Wan-Hsuan Lee , Chien-Chin Lin , Xavier Cheng-Hong Tsai , Feng-Ming Tien , Min-Yen Lo , Yuan-Yeh Kuo , Shan-Chi Yu , Ming-Chih Liu , Chang-Tsu Yuan , Ming Yao , Bor-Sheng Ko , Hwei-Fang Tien , Hsin-An Hou , Wen-Chien Chou","doi":"10.1016/j.clml.2024.12.021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Myelodysplastic syndromes/neoplasms (MDS) are a diverse group of clonal myeloid disorders. Advances in molecular technology lead to the development of new classification systems. However, large-scale epidemiological studies on MDS in Asian countries are currently scarce.</div></div><div><h3>Patients</h3><div>Data were retrospectively collected from 1,095 patients with primary MDS, Patients with prior chemotherapy, radiotherapy, or hematologic malignancies were excluded.</div></div><div><h3>Methods</h3><div>Patients with cryopreserved bone marrow (BM) samples were sequenced using the TruSight Myeloid Panel and HiSeq platform. KaplanMeier analysis was used to generate survival curves, with significance assessed via the log-rank test.</div></div><div><h3>Results</h3><div>This analysis revealed significant changes in MDS subtypes, treatments, and prognoses over time, with more patients receiving hypomethylating agents (HMA) with and without venetoclax and allogeneic hematopoietic stem cell transplantation (HSCT) in recent years. Survival analysis revealed that both IPSS-R and IPSS-M did well stratified MDS patients and improved outcomes in the patients who underwent HSCT. Although the number of patients was limited in current study, combination therapy with HMA and venetoclax resulted in improved treatment responses and a higher rate of successful bridging to HSCT. These findings underscore the need for further large-scale studies to investigate the impact of combination treatment on MDS patients undergoing transplantation.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 6","pages":"Pages e336-e347.e14"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024024789","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Myelodysplastic syndromes/neoplasms (MDS) are a diverse group of clonal myeloid disorders. Advances in molecular technology lead to the development of new classification systems. However, large-scale epidemiological studies on MDS in Asian countries are currently scarce.

Patients

Data were retrospectively collected from 1,095 patients with primary MDS, Patients with prior chemotherapy, radiotherapy, or hematologic malignancies were excluded.

Methods

Patients with cryopreserved bone marrow (BM) samples were sequenced using the TruSight Myeloid Panel and HiSeq platform. KaplanMeier analysis was used to generate survival curves, with significance assessed via the log-rank test.

Results

This analysis revealed significant changes in MDS subtypes, treatments, and prognoses over time, with more patients receiving hypomethylating agents (HMA) with and without venetoclax and allogeneic hematopoietic stem cell transplantation (HSCT) in recent years. Survival analysis revealed that both IPSS-R and IPSS-M did well stratified MDS patients and improved outcomes in the patients who underwent HSCT. Although the number of patients was limited in current study, combination therapy with HMA and venetoclax resulted in improved treatment responses and a higher rate of successful bridging to HSCT. These findings underscore the need for further large-scale studies to investigate the impact of combination treatment on MDS patients undergoing transplantation.

查看原文本刊更多论文

台湾骨髓增生异常综合征/肿瘤的流行病学、治疗结果与预后：真实世界的见解与趋势。

背景：骨髓增生异常综合征/肿瘤（MDS）是一组不同的克隆性骨髓疾病。分子技术的进步导致了新的分类系统的发展。然而，目前亚洲国家对MDS的大规模流行病学研究很少。患者：回顾性收集了1095例原发性MDS患者的数据，排除了既往有化疗、放疗或血液恶性肿瘤的患者。方法：使用TruSight髓系面板和HiSeq平台对冷冻保存的骨髓（BM）样本进行测序。采用KaplanMeier分析生成生存曲线，通过log-rank检验评估显著性。结果：随着时间的推移，该分析揭示了MDS亚型、治疗和预后的显著变化，近年来越来越多的患者接受了低甲基化药物（HMA）联合或不联合venetoclax和异体造血干细胞移植（HSCT）。生存分析显示，IPSS-R和IPSS-M对MDS患者分层效果良好，并改善了接受HSCT患者的预后。虽然目前的研究中患者数量有限，但HMA和venetoclax联合治疗改善了治疗反应，并且成功桥接到HSCT的比例更高。这些发现强调需要进一步的大规模研究来调查联合治疗对移植MDS患者的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.